Emerging studies suggest Retatrutide , a dual activator targeting both incretin and GIP , appears to offer a promising development for obesity loss . Preliminary clinical investigations have shown impressive losses in visceral fat , potentially surpassing existing body composition treatments. However , additional study is needed to fully determine